| |
Imclone<IMCL.O> sees cancer vaccine trial, Q4 loss
DANA POINT, Calif, March 3 (Reuters) - ImClone Systems Inc chief operating officer Harlan Waksal said it and Merck KgaA will soon begin a Phase III multinational clinical study for its cancer vaccine BEC-2.
Waksal also said he was comfortable with analysts' estimates of a $0.15 per share loss for the fourth quarter of 1997 and a full year loss of $0.61 a share for the year just ended in December.
At the Cruttenden Roth Growth STock Conference, he said the study involving 600 patients will begin within a month, pending authorization from all the participating medical institutions.
In a pilot study, the vaccine has shown prolonged survival of patients with small cell lung cancer.
Waksal also said he hopes the company's lead product, C225, a cancer therapeutic treatment, will be in the marketplace by the end of 1999.
16:15 03-03-98
Copyright 1998 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similiar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All active hyperlinks have been inserted by AOL. |
|
